不良研究所

不良研究所 launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...

Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...

Offering will provide robust, standardised tools for research and drug discovery.

Weslie Janeway - investor, philanthropist, and scientist - joins 不良研究所's Board of Directors.

This collaboration will combine the Mekonos novel ex vivo delivery platform with 不良研究所鈥檚 opti-ox precision cellular reprogrammin...

Statement from our CFO on the situation concerning SVB.

不良研究所 will use Automata to automate a key aspect of its production of iPSC derived human cells

New advisors will provide important and independent guidance.